02.24.25 -- CDMOs Bet Big On Asia Expansion. Can Trump Reverse The Tide?

Join us on March 6th with Singota to explore strategies for scaling up drug development from bench to Phase 1 clinical trials. Learn how to navigate cold chain logistics, develop robust analytical methods, and avoid compromising your core values. Discover insights from Singota’s 20+ years of experience helping early-stage biopharma teams succeed. Click here to learn more.

Human errors account for many manufacturing failures, simply due to the roles in our activities and systems. Relational risk analysis (ReRA) fundamentally changes the way risks are analyzed.

Leveraging the expertise of a chosen clinical supply partner can be a valuable resource. Examine key considerations when partnering with a CRO in order to deliver a successful clinical supply strategy.

The key to navigating the biologic development journey lies in CMC. By analyzing and characterizing the drug's properties, CMC teams ensure a smooth path from bench to patient care.

Explore the vital role of drug formulation in transforming biologics into patient-friendly therapies, and uncover key insights into this critical process from lab to clinical trials.

The formulations for novel therapeutics require flexibility to support adaptive sterile manufacturing and an integrated approach for a path from development through commercialization.

Discover how implementing a strategic approach to optimize the platform can establish a solid foundation for the efficient, reliable, and successful manufacturing of biopharmaceutical products.

CDMO proposals often vary in level of detail and depth of explanation, preventing a lateral comparison. However, CDMO clients can take steps to ensure more uniformity between competing offers.

To accelerate COVID-19 vaccine production, a leading biologics contract manufacturer sought high-speed labeling machines that could be rapidly deployed.

Facing challenges transferring your biological product from development to manufacturing? Delve into strategies for tech transfer processes, ensuring regulatory compliance, quality, and consistency.

While the Brisbane facility’s key value is facilitating development and industrialization of new bacterial strains, how this is accomplished separates it from would-be competitors.

Over the years we’ve learned invaluable lessons in the development of large molecule biologics and share our project management experience to support our customers’ drug strategies.

Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.

Over the course of 30+ years we’ve invested in and developed a broad range of expertise, a full suite of lab and analytical services, advanced technology platforms and a world-class facilities network.

Our partnerships with NavVis Digital Twin Technology and Prevu3D empower us to create detailed 3D representations of your systems, facilities, operations, and real-time data.

Curia is now part of a powerful global network of 3,700+, with 29 global locations. Our integrated solutions and capabilities bridge discovery, engineering, development, and manufacturing across sites.